Selena Dozier, MD
Family Medicine · Union City, TNNPI 1023253119
Payments from drug & device makers
Across 468 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$596
- Amgen$553
- Takeda Pharmaceuticals U.S.A., Inc.$515
- Pfizer$487
- Johnson & Johnson$477
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,07598%
- Education$1392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 131 | $1,852 |
| Lilly USA, LLC | 37 | $596 |
| Amgen | 42 | $553 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $515 |
| Pfizer | 40 | $487 |
| Johnson & Johnson | 25 | $477 |
| Boehringer Ingelheim | 29 | $469 |
| AstraZeneca(2 entities) | 18 | $408 |
| AbbVie | 22 | $308 |
| Abbott | 9 | $203 |
| Merck | 20 | $193 |
| Otsuka America Pharmaceutical, Inc. | 7 | $156 |
| Novartis | 12 | $129 |
| Sanofi-aventis U.S. LLC | 6 | $128 |
| Phathom Pharmaceuticals, Inc. | 8 | $115 |
| Astellas Pharma US Inc | 1 | $94 |
| Dexcom, Inc. | 4 | $84 |
| GSK | 4 | $73 |
| Eisai Inc. | 4 | $67 |
| Sanofi Pasteur Inc. | 5 | $63 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $40 |
| Exact Sciences | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 2 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$152
- SYMBICORT$152
- BEVESPI AEROSPHERE$152
How this compares
$7,214 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 137 | $135,387 |
| OzempicSemaglutide | 107 | $103,567 |
| EliquisApixaban | 90 | $55,554 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $46,151 |
| RybelsusSemaglutide | 22 | $40,543 |
| Teriparatide | 16 | $35,806 |
| XareltoRivaroxaban | 42 | $35,427 |
| MounjaroTirzepatide | 31 | $31,495 |
| EntrestoSacubitril/Valsartan | 21 | $22,370 |
| TrulicityDulaglutide | 14 | $20,559 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $19,650 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,145 |
| FarxigaDapagliflozin Propanediol | 23 | $17,356 |
| JanuviaSitagliptin Phosphate | 13 | $15,715 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $13,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $469 | $149,033151 claims |
| Novo NordiskOzempic, Rybelsus | $1,852 | $144,109129 claims |
| PfizerEliquis | $487 | $55,55490 claims |
| Lilly USA, LLCMounjaro, Trulicity | $596 | $52,05445 claims |
| Johnson & JohnsonXarelto | $477 | $35,42742 claims |
| MerckJanumet, Januvia | $193 | $35,36531 claims |
| NovartisEntresto | $129 | $22,37021 claims |
| GSKTrelegy Ellipta | $73 | $18,14523 claims |
| AstraZenecaFarxiga | $408 | $17,35623 claims |
| AbbVieSynthroid | $308 | $8,155122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Union City
- James BateyUnion City$66K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.